FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025122144> ?p ?o ?g. }

• W3025122144 endingPage "253" @default.
• W3025122144 startingPage "249" @default.
• W3025122144 abstract "The association between dipeptidyl peptidase 4 inhibitors (DPP-4i) and bullous pemphigoid (BP) has been demonstrated in several studies. The main aim of this study was to estimate the use of DPP-4i treatment in patients diagnosed with BP in our setting. We selected patients histologically diagnosed with BP in our department between October 2015 and October 2018 and performed a retrospective chart review to assess clinical and epidemiological data and direct immunofluorescence (DIF) patterns. Of the 70 patients diagnosed with BP during the study period, 50% were diabetic and 88.57% of these were being treated with a DPP-4i when diagnosed with BP. The most common DPP-4i was linagliptin (used in 18.6% of patients), followed by vildagliptin (17.1%). The median latency period between initiation of DPP-4i treatment and diagnosis of BP was 27.5 months for all treatments, 16 months for linagliptin, and 39 months for vildagliptin (log rank < 0.01). A negative DIF result was significantly more common in patients not being treated with a DPP-4i. The DIF pattern most strongly (and significantly) associated with DPP-4i treatment was linear immunoglobulin G deposits along the dermal-epidermal junction. DPP-4i treatment was withdrawn in 87% of patients and 96% of these achieved a complete response. DPP-4i treatment is very common in patients with BP in our setting. The latency period between start of treatment and onset of BP seems to be shorter with linagliptin than with other types of gliptins. Patients receiving DPP-4i treatment may show different DIF patterns to those not receiving treatment. La asociación entre los inhibidores de la dipeptidil peptidasa 4 (iDPP-4) y el penfigoide ampolloso (PA) se ha demostrado en varios estudios. El objetivo principal de este estudio era estimar el uso del tratamiento con iDPP-4i en pacientes diagnosticados de PA en nuestro entorno. Seleccionamos pacientes diagnosticados histológicamente de PA en nuestro departamento entre octubre de 2015 y octubre de 2018. Realizamos una revisión retrospectiva para evaluar los datos clínicos-epidemiológicos y los patrones de inmunofluorescencia directa (IFD). De los 70 pacientes diagnosticados con PA durante el período de estudio, el 50% eran diabéticos y el 88,57% de ellos estaban siendo tratados con un iDPP-4 en el momento del diagnóstico de PA. El iDPP-4 más frecuente era la linagliptina (utilizada en el 18,6% de los pacientes), seguida de la vildagliptina (el 17,1%). La mediana de tiempo de latencia entre el inicio del tratamiento con iDPP-4 y el diagnóstico de PA fue de 27,5 meses, siendo de 16 meses para la linagliptina y 39 meses para la vildagliptina (log Rank < 0,01). La IFD fue negativaUn resultado negativo de DIF fue significativamente más común en pacientes que no fueron tratados con un DPP-4i. El patrón DIF más fuertemente (y significativamente) asociado con el tratamiento con DPP-4i fueron los depósitos lineales de inmunoglobulina G a lo largo de la unión dermoepidérmica. El tratamiento con DPP-4i se retiró en el 87% de los pacientes y el 96% de ellos logró una respuesta completa. El tratamiento con DPP-4i es muy común en pacientes con BP en nuestro entorno. El período de latencia entre el inicio del tratamiento y el inicio de la PA parece ser más corto con linagliptina que con otros tipos de gliptinas. Los pacientes que reciben tratamiento con DPP-4i pueden mostrar patrones DIF diferentes a los que no reciben tratamiento." @default.
• W3025122144 created "2020-05-21" @default.
• W3025122144 creator A5025017015 @default.
• W3025122144 creator A5032013277 @default.
• W3025122144 creator A5032484568 @default.
• W3025122144 creator A5037854766 @default.
• W3025122144 creator A5040293440 @default.
• W3025122144 creator A5042367385 @default.
• W3025122144 creator A5048825447 @default.
• W3025122144 creator A5049456418 @default.
• W3025122144 creator A5049756726 @default.
• W3025122144 creator A5051360084 @default.
• W3025122144 creator A5058190776 @default.
• W3025122144 creator A5059252811 @default.
• W3025122144 creator A5059942476 @default.
• W3025122144 creator A5073662846 @default.
• W3025122144 creator A5073686241 @default.
• W3025122144 creator A5079504653 @default.
• W3025122144 creator A5083952762 @default.
• W3025122144 creator A5084537446 @default.
• W3025122144 date "2020-04-01" @default.
• W3025122144 modified "2023-10-17" @default.
• W3025122144 title "Association Between Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Cohort Study" @default.
• W3025122144 cites W1896853883 @default.
• W3025122144 cites W2135033359 @default.
• W3025122144 cites W2288299997 @default.
• W3025122144 cites W2460874082 @default.
• W3025122144 cites W2778763028 @default.
• W3025122144 cites W2785773046 @default.
• W3025122144 cites W2797121854 @default.
• W3025122144 cites W2800257361 @default.
• W3025122144 cites W2801732660 @default.
• W3025122144 cites W2809062680 @default.
• W3025122144 cites W2819950008 @default.
• W3025122144 cites W2887766728 @default.
• W3025122144 cites W2888311773 @default.
• W3025122144 cites W2905143632 @default.
• W3025122144 doi "https://doi.org/10.1016/j.adengl.2020.03.011" @default.
• W3025122144 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31864538" @default.
• W3025122144 hasPublicationYear "2020" @default.
• W3025122144 type Work @default.
• W3025122144 sameAs 3025122144 @default.
• W3025122144 citedByCount "5" @default.
• W3025122144 countsByYear W30251221442020 @default.
• W3025122144 countsByYear W30251221442021 @default.
• W3025122144 countsByYear W30251221442023 @default.
• W3025122144 crossrefType "journal-article" @default.
• W3025122144 hasAuthorship W3025122144A5025017015 @default.
• W3025122144 hasAuthorship W3025122144A5032013277 @default.
• W3025122144 hasAuthorship W3025122144A5032484568 @default.
• W3025122144 hasAuthorship W3025122144A5037854766 @default.
• W3025122144 hasAuthorship W3025122144A5040293440 @default.
• W3025122144 hasAuthorship W3025122144A5042367385 @default.
• W3025122144 hasAuthorship W3025122144A5048825447 @default.
• W3025122144 hasAuthorship W3025122144A5049456418 @default.
• W3025122144 hasAuthorship W3025122144A5049756726 @default.
• W3025122144 hasAuthorship W3025122144A5051360084 @default.
• W3025122144 hasAuthorship W3025122144A5058190776 @default.
• W3025122144 hasAuthorship W3025122144A5059252811 @default.
• W3025122144 hasAuthorship W3025122144A5059942476 @default.
• W3025122144 hasAuthorship W3025122144A5073662846 @default.
• W3025122144 hasAuthorship W3025122144A5073686241 @default.
• W3025122144 hasAuthorship W3025122144A5079504653 @default.
• W3025122144 hasAuthorship W3025122144A5083952762 @default.
• W3025122144 hasAuthorship W3025122144A5084537446 @default.
• W3025122144 hasBestOaLocation W30251221441 @default.
• W3025122144 hasConcept C126322002 @default.
• W3025122144 hasConcept C134018914 @default.
• W3025122144 hasConcept C156490143 @default.
• W3025122144 hasConcept C159654299 @default.
• W3025122144 hasConcept C167135981 @default.
• W3025122144 hasConcept C181199279 @default.
• W3025122144 hasConcept C185592680 @default.
• W3025122144 hasConcept C203014093 @default.
• W3025122144 hasConcept C2776453732 @default.
• W3025122144 hasConcept C2777180221 @default.
• W3025122144 hasConcept C2778384471 @default.
• W3025122144 hasConcept C2778763485 @default.
• W3025122144 hasConcept C2779252107 @default.
• W3025122144 hasConcept C2779306644 @default.
• W3025122144 hasConcept C2780031085 @default.
• W3025122144 hasConcept C2780323712 @default.
• W3025122144 hasConcept C2781469919 @default.
• W3025122144 hasConcept C2910068830 @default.
• W3025122144 hasConcept C55493867 @default.
• W3025122144 hasConcept C555293320 @default.
• W3025122144 hasConcept C71924100 @default.
• W3025122144 hasConcept C72563966 @default.
• W3025122144 hasConcept C90924648 @default.
• W3025122144 hasConceptScore W3025122144C126322002 @default.
• W3025122144 hasConceptScore W3025122144C134018914 @default.
• W3025122144 hasConceptScore W3025122144C156490143 @default.
• W3025122144 hasConceptScore W3025122144C159654299 @default.
• W3025122144 hasConceptScore W3025122144C167135981 @default.
• W3025122144 hasConceptScore W3025122144C181199279 @default.
• W3025122144 hasConceptScore W3025122144C185592680 @default.
• W3025122144 hasConceptScore W3025122144C203014093 @default.
• W3025122144 hasConceptScore W3025122144C2776453732 @default.

• next